In-vivo behavior of tin-radiopharmaceuticals

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

In-vivo behavior of tin-radiopharmaceuticals

HE Jia-Heng，

LUO Shun-Zhong，

WANG Guan-Quan，

YANG Yu-Qing，

PU Man-Fei，

LIU Guo-Ping

Nuclear Science and Techniques

Vol.14, No.2

pp.127-130

Published in print 01 May 2003

CLC：R817.4,O613.44

24700

Tin is an essential ingredient of most technetium-99m radiopharmaceuticals but its in-vivo distribution and long-term fate are not well understood. This work describes distribution in mice of several tin-117m labeled compounds. The results indicate that stannic-HEDTMP appears to be the best overall bone localizing agent with very low blood, muscle, kidney, or liver uptake, and its binding to bone is higher than that of tin-117m-DTPA, which make it potentially useful as an agent for skeletal scintigraphy and radiotherapy of bone tumors.

117mSnHEDTMPBone tumor

References

[1]

Srivastava S C, Richards P, Meinken G E et al. Nucl Med Biol, 1982, 2: 1635-1638

[2]

Som P, Srivastava S C, Oster Z H et al. J Nucl Med, 1982, 23: 78

[3]

Yano Y, Chu P, Anger H O. Int J Appl Radiat Isot, 1973, 24: 319-325

[4]

Srivastava S C, Meinken G E, Richards P et al. Int J Nucl Med Biol, 1985, 12: 167-174

[5]

Atkins H L, Mausner L F, Srivastava S C et al. Int J Nucl Med, 1995, 36: 725-732

[6]

Atkins H L, Mausner L F, Srivastava S C et al. Radiology, 1993, 186: 279-283